UNSPSC 51112007: Semaxanib

This classification denotes a tyrosine kinase inhibitor with the molecular formula C15H14N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71IA9S35AJ, chemically known as 3-((z)-(3,5-dimethylpyrrol-2-yl)methylene)-2-indolinone but generally known as semaxanib, which bears US NIH Compound Identifier 5329098. European Medicines Agency schedules Semaxanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32269.

UNSPSC 51112007 Semaxanib is a Commodity code representing pharmaceutical products supplied through cooperative purchasing agreements to state and local government healthcare facilities. State and local buyers under this code procure generic pharmaceuticals and over-the-counter (OTC) products through established wholesale distribution channels, with pricing and product specifications negotiated at the multistate or individual-jurisdiction level. The work involves vendor supply of identified pharmaceutical products with specific National Drug Codes (NDC), SKUs, and packaging configurations; compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA); maintenance of contractual relationships with authorized pharmaceutical wholesalers; and fulfillment of performance and reporting obligations tied to cooperative purchasing agreements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and agree to a 3 percent administrative fee on all contract purchases. Evaluation is weighted toward price competitiveness (75 percent), with secondary weight on fixed pricing, compliance with data format requirements, EDI capability, and agreement to the administrative fee structure. Awarded vendors will be effective July 1, 2026, with a contract term of two years for new responders and optional extensions at MMCAP's discretion.